Programs Anti-Aging

Currently, industry analysts project the anti-aging marketplace will exceed $191.7 billon by 2019, driven by an insatiable demand to defy the signs of aging. While baby boomers spend more on personal care than any other age group and control about 70% of America’s wealth, young consumers are also taking more preventative measures to maintain their youthful-looking skin. Men are spending more on anti-aging products as well.

Despite the number of anti-aging ingredients available there is growing demand for new, scientifically-proven anti-aging products. More than ever, consumers are requiring data to support their decisions, particularly in Japan and the western world, and are driving the need for companies to prove that their products are truly effective.

With the skincare market forecasted to continue double digit growth in the foreseeable future, there is a significant opportunity for new, scientifically proven, safe and effective ingredients.

Sirona Biochem’s Glycoproteins

Sirona Biochem is developing an anti-aging compound library based on the naturally occurring antifreeze glycoproteins found in Antarctic fish. In the late 1960s Professor Arthur DeVries established that the resistance to freezing temperatures in Antarctic fish was due to blood serum glycoproteins that protected the fish cells against the stressful Antarctic environment. Our studies have shown that these glycoproteins protect not only against freezing, but also against environmental stressors such as UV light, oxidation and nutrient deprivation.

Our patented anti-aging compounds derived from our proprietary chemistry technology can potentially protect people’s skin cells against many of the stresses presented by natural aging and environmental effects.

Anti-Aging Project Status

Sirona Biochem has created a library of anti-aging compounds and has begun studies testing each compound’s effectiveness in anti-aging and conditions related to skin cell damage.  80% of visual aging is related to cell death; we believe our compounds can protect these skin cells from damage, allowing them to live longer.

  • In a previous study, Sirona Biochem’s anti-aging compounds kept 95% of the protected skin cells alive for 7 days compared to the unprotected control group where only 8% of the unprotected cells were still alive after 7 days.

Adjuvants for Biological Preservation Status

Our scientists are developing part of the portfolio as adjuvants to be used for organ, tissue and cells preservation.

Research shows that freezing resistance in Antarctic fish is due to blood serum glycoproteins that lower the freezing temperature to below subzero.  This helps inhibit the growth of ice and protects cells from hypothermic damage.  These antifreeze glycoproteins have an unusual structure that can protect species from cold induced damage.

By mimicking these glycoproteins, modified glycopeptides can be developed to protect organs destined for transplant.  Currently, heart and lungs can be preserved for up to six hours, limiting its transport time for organ transplantation.  By developing these modified glycopeptides, we aim to preserve the integrity of organs for a longer period of time, leading to an expanded geographical reach for organ matching and transplantation.  Our goal is to develop a family of compounds with specific applications for soft tissue, stem cells, islet cells and other sensitive cells preservation.

Sirona Biochem’s subsidiary, TFChem, has worked extensively on the development of new processes to prepare families of modified glycopeptides.  Our scientists are the first to have developed these types of compounds (Patent EP10306493). Numerous in-vitro studies have shown the protective role against various stressors in skin cells. A full genomic study has also been completed to provide valuable information on the mechanism of action of the library.

Sirona Biochem’s expertise lies in creating innovative, proprietary technology which can be leveraged by leading companies within the cosmetic, biotechnology and pharmaceutical marketplaces. Our technology can be commercialized in partnership through, but not limited to, the following types of agreements:

  • Licensing Agreements
  • Royalty Agreements
  • Acquisition of our technology
  • Joint ventures

For any additional information please contact Michelle Seltenrich at